vs
Canopy Growth Corp（CGC）与Mind Medicine (MindMed) Inc.（DFTX）财务数据对比。点击上方公司名可切换其他公司
Canopy Growth Corp的季度营收约是Mind Medicine (MindMed) Inc.的60.1倍（$54.4M vs $906.0K）。Canopy Growth Corp净利率更高（-84.0% vs -2634.0%，领先2550.0%）。Canopy Growth Corp同比增速更快（-0.3% vs -16.1%）
Canopy Growth Corp前身为Tweed Marijuana Inc，是一家总部位于加拿大安大略省史密斯福尔斯的大麻企业，在北美大麻行业拥有较高知名度，主要从事大麻相关产品的研发、生产与销售业务。
Definium Therapeutics（前称MindMed）是一家总部位于纽约的生物技术企业，专注于致幻剂及更广泛的精神可塑性药物的临床与治疗应用开发，在中枢神经药物研发领域深耕相关创新疗法的落地潜力。
CGC vs DFTX — 直观对比
营收规模更大
CGC
是对方的60.1倍
$906.0K
营收增速更快
CGC
高出15.8%
-16.1%
净利率更高
CGC
高出2550.0%
-2634.0%
损益表 — Q3 2026 vs Q4 2023
| 指标 | | |
|---|---|---|
| 营收 | $54.4M | $906.0K |
| 净利润 | $-45.7M | $-23.9M |
| 毛利率 | 28.8% | — |
| 营业利润率 | -35.3% | -2450.8% |
| 净利率 | -84.0% | -2634.0% |
| 营收同比 | -0.3% | -16.1% |
| 净利润同比 | 48.6% | -386.7% |
| 每股收益（稀释后） | — | $-0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CGCDFTX
| Q4 25 | $54.4M | — | ||
| Q3 25 | $48.7M | — | ||
| Q2 25 | $52.7M | — | ||
| Q1 25 | $47.5M | — | ||
| Q4 24 | $54.6M | — | ||
| Q3 24 | $46.0M | — | ||
| Q2 24 | $48.3M | — | ||
| Q1 24 | $53.1M | — |
净利润CGCDFTX
| Q4 25 | $-45.7M | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-30.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-89.0M | — | ||
| Q3 24 | $-93.7M | — | ||
| Q2 24 | $-92.8M | — | ||
| Q1 24 | — | — |
毛利率CGCDFTX
| Q4 25 | 28.8% | — | ||
| Q3 25 | 32.8% | — | ||
| Q2 25 | 25.0% | — | ||
| Q1 25 | 16.2% | — | ||
| Q4 24 | 32.2% | — | ||
| Q3 24 | 34.7% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 21.3% | — |
营业利润率CGCDFTX
| Q4 25 | -35.3% | — | ||
| Q3 25 | -25.3% | — | ||
| Q2 25 | -31.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -31.9% | — | ||
| Q3 24 | -72.9% | — | ||
| Q2 24 | -44.0% | — | ||
| Q1 24 | — | — |
净利率CGCDFTX
| Q4 25 | -84.0% | — | ||
| Q3 25 | -2.5% | — | ||
| Q2 25 | -57.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -163.0% | — | ||
| Q3 24 | -203.7% | — | ||
| Q2 24 | -192.0% | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $271.1M | $99.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $553.5M | $78.1M |
| 总资产 | $807.5M | $124.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CGCDFTX
| Q4 25 | $271.1M | — | ||
| Q3 25 | $217.6M | — | ||
| Q2 25 | $104.8M | — | ||
| Q1 25 | $96.0M | — | ||
| Q4 24 | $130.2M | — | ||
| Q3 24 | $168.8M | — | ||
| Q2 24 | $142.3M | — | ||
| Q1 24 | $148.5M | — |
股东权益CGCDFTX
| Q4 25 | $553.5M | — | ||
| Q3 25 | $537.3M | — | ||
| Q2 25 | $357.0M | — | ||
| Q1 25 | $355.7M | — | ||
| Q4 24 | $431.8M | — | ||
| Q3 24 | $372.1M | — | ||
| Q2 24 | $389.0M | — | ||
| Q1 24 | $365.3M | — |
总资产CGCDFTX
| Q4 25 | $807.5M | — | ||
| Q3 25 | $781.0M | — | ||
| Q2 25 | $660.4M | — | ||
| Q1 25 | $669.9M | — | ||
| Q4 24 | $849.9M | — | ||
| Q3 24 | $899.6M | — | ||
| Q2 24 | $938.9M | — | ||
| Q1 24 | $949.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-20.6M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CGCDFTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-7.5M | — | ||
| Q1 25 | $-121.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-37.8M | — | ||
| Q1 24 | $-205.8M | — |
自由现金流CGCDFTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $-128.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-40.7M | — | ||
| Q1 24 | $-208.3M | — |
自由现金流率CGCDFTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -16.1% | — | ||
| Q1 25 | -271.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -84.1% | — | ||
| Q1 24 | -392.1% | — |
资本支出强度CGCDFTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 16.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 4.7% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CGC
| CA | $45.4M | 84% |
| International Markets Cannabis | $6.2M | 11% |
| Other | $1.5M | 3% |
| Other Geographical Area | $1.2M | 2% |
DFTX
暂无分部数据
